20484-2 |
Cardiolipin Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Cardiolipin IgG Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
COAG |
|
20484-2 |
|
|
|
|
Both |
|
|
|
0 |
Cardiolipin IgG Titr Ser |
|
|
|
Y |
|
ABS; Aby; ACA; aCL; Antby; Anti; Antibodies; Antibody; Anticardiolipin; Autoantibodies; Autoantibody; Cardio; Cardiolip; Cardiolipn; Cardiolpn; CL; COAGULATION; Dilution factor; Dilution Factor (Titer); Hematology; Heme; Immune globulin G; Immunoglobulin G; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0m |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
20485-9 |
Cardiolipin Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Cardiolipin IgM Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
COAG |
|
20485-9 |
|
|
|
|
Both |
|
|
|
0 |
Cardiolipin IgM Titr Ser |
|
|
|
Y |
|
ABS; Aby; ACA; aCL; Antby; Anti; Antibodies; Antibody; Anticardiolipin; Autoantibodies; Autoantibody; Cardio; Cardiolip; Cardiolipn; Cardiolpn; CL; COAGULATION; Dilution factor; Dilution Factor (Titer); Hematology; Heme; Immune globulin M; Immunoglobulin M; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0m |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
20486-7 |
Haemophilus influenzae B Ag |
ACnc |
CSF |
Pt |
Qn |
|
|
ACTIVE |
Haemophilus influenzae B Ag [Units/volume] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20486-7 |
|
|
|
|
Both |
|
|
|
0 |
Haem influ B Ag CSF-aCnc |
|
|
|
Y |
|
Antigen; Antigens; Arbitrary concentration; Cerebral spinal fluid; Cerebrospinal Fl; H flu; H influenza; H influenzae; Haem influ; Haem influ B; Haemoph; HIB; ID; Infectious Disease; InfectiousDisease; Influ; Microbiology; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.69 |
1.0m |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
20487-5 |
Neisseria meningitidis serogroups A+Y Ag |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Neisseria meningitidis serogroups A+Y Ag [Presence] in Cerebral spinal fluid |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20487-5 |
|
|
|
|
Both |
|
|
|
0 |
N men sg A+Y Ag CSF Ql |
|
|
|
|
|
Antigen; Antigens; Cerebral spinal fluid; Cerebrospinal Fl; ID; Infectious Disease; InfectiousDisease; Mening; Meningid; Meningitis; Meningo; Meningococcal meningitis; Meningococcus; Microbiology; N men; N men sg A+Y; N men sg A+Y Ag; N menigitidis; N meningitidis; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.64 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 'serogroup'added to the Component for clarification. |
0 |
20488-3 |
Streptococcus agalactiae Ag |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Streptococcus agalactiae Ag [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20488-3 |
|
|
|
|
Both |
|
|
|
0 |
Gp B Strep Ag CSF Ql |
|
|
|
|
|
Antigen; Antigens; Cerebral spinal fluid; Cerebrospinal Fl; GBS; Gp B Strep; Group B; Group B Strep; ID; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; S agalactiae; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Steptococcus Group B; Strep; Strep B; Strep group B; Strept; Streptococci group B |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
20489-1 |
Streptococcus pneumoniae Ag |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Streptococcus pneumoniae Ag [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20489-1 |
|
|
|
|
Both |
|
|
|
0 |
S pneum Ag CSF Ql |
|
|
|
|
|
Antigen; Antigens; Cerebral spinal fluid; Cerebrospinal Fl; ID; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Ordinal; Pneu; pneum; Pneumo; Pneumococ; Pneumococcal; Pneumococcal pneumonia; Pneumococcus; Pneumon; Pneumonia; Point in time; PR; QL; Qual; Qualitative; Random; S pneumo; S pneumoniae; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Spn; Strep; Strept |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
2049-5 |
Carnosine |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Carnosine [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
2049-5 |
|
|
|
|
Observation |
|
|
|
0 |
Carnosine SerPl Ql |
|
|
|
|
|
Car; Chemistry; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
20490-9 |
Epstein Barr virus capsid Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Epstein Barr virus capsid IgG Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
20490-9 |
|
|
|
|
Both |
|
|
|
0 |
EBV VCA IgG Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; CAP; Dilution factor; Dilution Factor (Titer); EBV; EBV capsid Ab; EBV VCA; Epstn; HHV-4; human herpesvirus 4; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Mono; Mononucleosis; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr; VCA; Viral capsid |
2.75 |
1.0m |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
20491-7 |
Epstein Barr virus capsid Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Epstein Barr virus capsid IgM Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
20491-7 |
|
|
|
|
Both |
|
|
|
0 |
EBV VCA IgM Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; CAP; Dilution factor; Dilution Factor (Titer); EBV; EBV capsid Ab; EBV VCA; Epstn; HHV-4; human herpesvirus 4; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Mono; Mononucleosis; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr; VCA; Viral capsid |
2.75 |
1.0m |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
20492-5 |
Hemoglobin pattern imp |
Imp |
Bld |
Pt |
Qn |
Electrophoresis |
|
DEPRECATED |
Deprecated Hemoglobin pattern [interpretation] in Blood by Electrophoresis Narrative |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
20492-5 |
|
Electrophoresis |
|
|
Observation |
|
|
|
0 |
Deprecated Hgb Bld Elph-Imp |
|
|
|
|
|
Blood; Elec; Elect; Electr; Electro; Electrophhrs; Electrophrs; Elp; Elph; Ep; Haemoglobin; Hb; HEMATOLOGY/CELL COUNTS; Hgb; Hgb Fract; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.36 |
1.0m |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
20493-3 |
Histiocytes/Cells |
NFr |
Body fld |
Pt |
Qn |
Microscopy.light |
|
ACTIVE |
Histiocytes/cells in Body fluid by Light microscopy |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
20493-3 |
|
Microscopy.light |
|
|
Observation |
|
|
|
0 |
Histiocytes NFr Fld Micro |
|
|
|
Y |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Cell; Cellularity; Fl; Fld; FLU; Fluid; HEMATOLOGY/CELL COUNTS; Histiocyte; Histocytes; LM; Micro; Micros; Microscopic; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.79 |
1.0m |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
20494-1 |
Lymphocytes/100 leukocytes |
NFr |
Body fld |
Pt |
Qn |
Manual count |
|
DEPRECATED |
Deprecated Lymphocytes/100 leukocytes in Body fluid by Manual count |
|
DEL |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
20494-1 |
|
Manual count |
|
|
Observation |
|
|
|
0 |
Deprecated Lymphocytes Fr Fld Manual |
|
|
|
|
|
100WBC; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Fl; Fld; FLU; Fluid; HEMATOLOGY/CELL COUNTS; Leuc; Leuk; Leukocyte; Lkcs; Lymp; Lymph; Lympho; Lymphocyte; Lymphs; Lymphs%; Manl; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WBC; WBCs; White blood cell; White blood cells |
2.36 |
1.0m |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
20495-8 |
Gliadin Ab.IgA |
ACnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Gliadin IgA Ab [Units/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
kEU/L |
|
|
|
|
|
|
SERO |
|
20495-8 |
|
IA |
|
|
Both |
|
|
|
0 |
Gliadin IgA Ser IA-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Celiac disease; EIA; ELFA; ELISA; Enzyme immunoassay; F98; Gliadine; IAA; Immune globulin A; Immunoglobulin A; MEIA; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR; SUDS; UniversalLabOrders |
2.73 |
1.0m |
|
|
|
|
|
|
|
[arb'U]/L |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
20496-6 |
Gliadin Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Gliadin IgG Ab [Units/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
kEU/L |
|
|
|
|
|
|
SERO |
|
20496-6 |
|
IA |
|
|
Both |
|
|
|
0 |
Gliadin IgG Ser IA-aCnc |
|
|
|
Y |
|
ABS; Aby; Agf98; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Celiac disease; EIA; ELFA; ELISA; Enzyme immunoassay; F98; Gliadine; IAA; Immune globulin G; Immunoglobulin G; MEIA; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR; SUDS; UniversalLabOrders |
2.73 |
1.0m |
|
|
|
|
|
|
|
[arb'U]/L |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
20497-4 |
Histoplasma capsulatum mycelial phase Ab |
ACnc |
Ser |
Pt |
Qn |
Comp fix |
|
ACTIVE |
Histoplasma capsulatum mycelial phase Ab [Units/volume] in Serum by Complement fixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20497-4 |
|
Comp fix |
|
|
Both |
|
|
|
0 |
H capsul Myc Ab Ser CF-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; CF; Comp fixation; Compfix; Complement fixation; H capsul; H capsul Myc; H capsulatum; H farciminosum; Histo; Histopl; Histoplasma farciminosum; Histoplasmin; Histoplasmos; Histoplasmosis; ID; Infectious Disease; InfectiousDisease; Microbiology; Mycel; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.69 |
1.0m |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
20498-2 |
Histoplasma capsulatum yeast phase Ab |
ACnc |
Ser |
Pt |
Qn |
Comp fix |
|
ACTIVE |
Histoplasma capsulatum yeast phase Ab [Units/volume] in Serum by Complement fixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20498-2 |
|
Comp fix |
|
|
Both |
|
|
|
0 |
H capsul Yst Ab Ser CF-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; CF; Comp fixation; Compfix; Complement fixation; H capsul; H capsul Yst; H capsulatum; H farciminosum; Histo; Histopl; Histoplasma farciminosum; Histoplasmos; Histoplasmosis; ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.69 |
1.0m |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
20499-0 |
Phosphatidylglycerol/Surfactant.total |
MFr |
Amnio fld |
Pt |
Qn |
|
|
ACTIVE |
Phosphatidylglycerol/Surfactant.total in Amniotic fluid |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CHEM |
|
20499-0 |
|
|
|
|
Observation |
|
|
|
0 |
PG MFr Amn |
|
|
|
Y |
|
AF; Amn; Amn fl; Amnio; Amniotic flu; Amniotic fluid; Chemistry; Fetal lung maturity; Mass fraction; Percent; PG; Phosphatidyl Glycerol; Phosphotidylglycerol; Point in time; QNT; Quan; Quant; Quantitative; Random; Tot; Totl |
2.73 |
1.0m |
|
|
|
|
|
|
|
% |
|
|
|
0 |
205-5 |
Colistin |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Colistin [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
205-5 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Colistin Islt MIC |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Colmycin; Colymycin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
2050-3 |
Carnosine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Carnosine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
2050-3 |
|
|
|
|
Observation |
|
|
|
0 |
Carnosine SerPl-mCnc |
|
|
|
Y |
|
Car; Chemistry; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.44 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
20500-5 |
Hydroxyalprazolam |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Hydroxyalprazolam [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
20500-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
OH-Alpraz Ur Cfm-mCnc |
|
|
|
Y |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; Hydroxy alprazolam; Hydroxyalpraz; LC/MS/MS; Level; Mass concentration; OH-Alpraz; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1.0m |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
20501-3 |
Hydroxytriazolam |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Hydroxytriazolam [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
20501-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
OH-Triazolam Ur Cfm-mCnc |
|
|
|
Y |
|
Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Hydroxy triazolam; Illicit; LC/MS/MS; Level; Mass concentration; OH-Triazolam; OHTRZ; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Triazolam metabolite; UA; UR; Urn |
2.73 |
1.0m |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
20502-1 |
Clue cells |
PrThr |
Vag |
Pt |
Ord |
Wet preparation |
|
ACTIVE |
Clue cells [Presence] in Vaginal fluid by Wet preparation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20502-1 |
|
Wet preparation |
|
|
Both |
|
|
|
0 |
Clue Cells Vag Ql Wet Prep |
|
|
|
|
|
Cell; Cellularity; Genital vaginal; Gyn; Gynecology; ID; Infectious Disease; InfectiousDisease; Microbiology; OB; ObGyn; Obstetrics; Ordinal; Point in time; PR; Prep; QL; Qual; Qualitative; Random; Screen; Vag fld; Vag fluid; Vagina; Vaginal fluid; Vaginosis; Wet mount; Wet prep |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
20503-9 |
Cells.CD22+CD11c+/Cells |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD22+CD11c+ cells/cells in Blood |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
20503-9 |
|
|
|
|
Observation |
|
|
|
0 |
CD22+CD11c+ Cells NFr Bld |
|
|
|
Y |
|
AlphaX integrin chain; Axb2; B3; B-3; BL-CAM; Blood; CD22 Cells; CD22+CD11c+ Cells; Cell; CELL MARKERS; Cellularity; CR4; Leu14; Leu-14; leukocyte surface antigen p150,95; LeuM5; Leu-M5; Lyb8; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; To-15; WB; Whole blood |
2.79 |
1.0m |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
20504-7 |
Histiocytes/Cells |
NFr |
CSF |
Pt |
Qn |
|
|
ACTIVE |
Histiocytes/cells in Cerebral spinal fluid |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
20504-7 |
|
|
|
|
Observation |
|
|
|
0 |
Histiocytes NFr CSF |
|
|
|
Y |
|
Cell; Cellularity; Cerebral spinal fluid; Cerebrospinal Fl; HEMATOLOGY/CELL COUNTS; Histiocyte; Histocytes; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.79 |
1.0m |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
20505-4 |
Bilirubin |
MCnc |
Urine |
Pt |
SemiQn |
Test strip |
|
ACTIVE |
Bilirubin.total [Mass/volume] in Urine by Test strip |
|
MAJ |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
UA |
|
20505-4 |
|
Test strip |
|
|
Observation |
|
|
|
0 |
Bilirub Ur Strip-mCnc |
|
|
|
Y |
|
Bili; Bilirubins; Billirubin; Dip stick; Dipstick; Level; Mass concentration; Point in time; Random; SmQn; TBIL; UA; UR; URINALYSIS; Urn |
2.75 |
1.0m |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |